The EU’s intellectual property system provides drugmakers with protection from competitors for a period of time. It is designed to recoup the often-high development costs and incentivize the industry to discover new and life-changing treatments. But there is strong debate over whether these incentives are too generous, and, also, being abused to block cheaper competition.

Organized in partnership with Sandoz, this event will bring together two expert teams for a head-to-head debate on the motion:

“This House believes that the EU’s intellectual property system strikes the right balance between incentives for medicines innovation and patient access”

https://www.politico.eu/event/safeguarding-innovation-and-empowering-faster-patient-access/?utm_source=Marketing-Cloud&utm_medium=Email&utm_campaign=-ROM3_-_program_announcement_onsite_-_Oxford_Style_debate#event-program